S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer

Sponsor
Korean Cancer Study Group
Study ID
NCT00343668
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • S-1, irinotecan — DRUG
    S-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1

Study Details

The primary goal of this phase II trial is to evaluate the response rate of combination chemotherapy with S-1 and Irinotecan in patients with advanced gastric cancer as a first-line therapy.

Key Dates

Start date
Sep 30, 2005
Status verified
Jun 2006
Primary completion
Mar 31, 2007
Completion
Jul 31, 2008

Study Design

Enrollment
44 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

response rate [ Time Frame: best response ]

Central Contacts

Related Studies